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Introduction
The primary goal of insulin therapy is to restore glycemic control [i.e., derived average glucose (A1C) <7% 1 or <6.5%] 2,3 as close to normal as practicable by mimicking the time-action profile of physiologic insulin. Postprandial plasma glucose (PPG) is increasingly being recognized as an important factor in reaching this goal, 3 especially as patients approach A1C target values. Indeed, postprandial hyperglycemia contributes the majority of total hyperglycemia for A1C values less than 8.5% and greater than 70% for A1C values less than 7.3%. 4, 5 Targets for postprandial glucose control have been established by several professional organizations.
The International Diabetes Federation and the American College of Endocrinology recommend that 2-hour postprandial values should be targeted below 140 mg/dl 2, 3 ; the American Diabetes Association recommends that peak postprandial glucose be targeted below 180 mg/dl. 1 Current rapid prandial insulin products have faster insulin pharmacokinetics (PK) and insulin action than regular insulin following subcutaneous (SC) injection, especially for low-to-moderate doses (≤0.2 U/kg or ≤16 units; Table 1) . 6, 7 Despite this improvement, most patients are still unable to reach glycemic goals even with currently available rapid-acting analog insulins. 15 Ultrafast insulin products are being developed that provide an even more rapid PK profile compared with current rapid prandial insulin products. 10, 16, 17 For example, an inhaled, dry powder insulin formulation has been developed that has a substantially faster time to peak plasma concentration (t max ) vs regular human insulin (12 to 17 minutes vs 2 hours postdose, respectively) and a more rapid return to baseline insulin concentrations (42 to 50 minutes) vs regular insulin (284 minutes). 17 The overall strategy of these ultrafast insulin products is to better mimic the normal physiologic response to insulin that occurs in healthy individuals to provide important clinical benefits in the control of postprandial hyperglycemic excursions. Some of these ultrafast insulin formulations have demonstrated additional benefits, such as reduced weight gain and fewer hypoglycemic events, compared with regular human insulin 18 or rapid-acting insulin analogs. [19] [20] [21] Recombinant human hyaluronidase (rHuPH20) is approved by the U.S. Food and Drug Administration for administration as an adjuvant to increase the absorption and dispersion of other injected drugs. 22 This genetically engineered enzyme lacks the C-terminal membrane-anchoring domain, rendering it soluble.
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A proof-of-concept study in which healthy volunteers were administered rHuPH20 with or without regular human insulin or insulin analog demonstrated an acceleration of PK profiles for both insulin formulations. 10 Coadministration of rHuPH20 increased the peak plasma concentration (C max ) by 90% for insulin lispro and 142% for regular insulin and reduced the t max by 51% for insulin lispro and 58% for regular insulin. In addition, coadministration of rHuPH20 reduced the intersubject variability for various PK and glucodynamic measures. 10 These faster PK results with rHuPH20 coadministration were confirmed and extended in two additional healthy volunteer studies [24] [25] [26] and during a meal study in patients with type 1 diabetes. 27 Results of the meal study demonstrated that the faster PK parameters reduced postmeal glycemic response without an increased risk of hypoglycemia. 27 The overall objectives of this review are to highlight the unmet needs even with the availability of current rapid-acting prandial products, to provide an overview of the history of hyaluronidase use and its mechanism of action in accelerating the absorption of coinjected drugs, and to review the emerging clinical pharmacology profile of prandial insulins coadministered with hyaluronidase.
Benefits and Limitations of Current Rapid-Acting Prandial Insulins
As summarized from a number of different studies, data shown in Table 2 demonstrate that rapid-acting insulin analogs reduce postprandial hyperglycemia relative to regular insulin injected at the same time. 16, [28] [29] [30] [31] [32] [33] These data also illustrate the impact of dose timing on glycemic response, such that in most cases, regular insulin administered approximately 30 to 60 minutes prior to a meal resulted in postprandial hyperglycemia comparable with rapid-acting analogs dosed 0 to 15 minutes before a meal.
However, these findings also demonstrate the limitations of current therapeutic offerings. Even with optimal dose timing in controlled laboratory settings, clinical targets for postprandial control are not met consistently. In the "real-world" setting, control of postprandial hyperglycemia is more challenging due to variations in dietary intake, insulin dose and timing, fear of hypoglycemia, and physical activity. 34 For example, it may be tempting for patients to dose prandial insulin immediately before meals to simplify lifestyle impacts of insulin treatment. Overall, clinical studies evaluating patient adherence to treatment and self-management of diabetes have consistently demonstrated the need for improvement, specifically with regard to self-monitoring, diet, and exercise. 15 
Enhanced Absorption through Hyaluronidase Coadministration

Mechanism of Action of Hyaluronidase
Hyaluronidase catalyzes the cleavage of the β1,4 linkage between N-acetylglucosamine and glucuronic acid residues of the hyaluronan long chain polymer, 35 and this breakdown of hyaluronan by hyaluronidase in the subcutaneous space results in enhanced permeation of coadministered agents. 22, 36 The rHuPH20 acts as a permeation enhancer and rapidly increases the dispersion of coinjected molecules in a dose-dependent manner ( Figure 1A) . 23 Because rHuPH20 is rapidly metabolized locally without systemic exposure 36 and hyaluronan has a rapid turnover (i.e., one-third of the total body pool of 15 grams turns over daily), 23 the permeation effects of rHuPH20 and hyaluronidase are transient (i.e., reconstitutes within 6 to 25 hours; Figure 1B ). Thus, both PH20 residence time and biochemical effects are transient and local, factors that suit it well for frequent and long-term use (as would be required for a prandial insulin product). Additionally, a favorable safety profile for rHuPH20 is supported by animal toxicology evaluations. 
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History of Hyaluronidase Administration
Over 60 years of clinical use support the safety and/ or efficacy of hyaluronidase coadministration with a variety of injected drugs. 10, 23, [38] [39] [40] [41] [42] The clinical safety and tolerability of hyaluronidase, which was first reported by Burket and Gyorgy in 1949, 38 have been established further with over 6 decades of use. 10, 23, [39] [40] [41] [42] Clinical history demonstrates the increased dispersion and faster absorption of a broad range of drugs and fluids administered with hyaluronidase products. 10, 23, [38] [39] [40] [41] [42] [43] [44] With rHuPH20, for example, Thomas and colleagues 45, 46 have demonstrated an accelerated PK profile of SC morphine coadministered with rHuPH20 compared with SC morphine alone, with earlier and greater peak exposure and comparable total bioavailability. Similarly, administration of rHuPH20 significantly enhanced gravity-driven SC infusion flow rates of fluid and electrolytes compared with placebo, leading the authors to suggest the possibility of using hyaluronidaseenabled SC infusions as replacements for pump-driven intravenous fluid therapy. 40 In keeping with the favorable safety profile of hyaluronidase as a class, rHuPH20 is well tolerated with a broad safety margin in a number of preclinical models. 36 Yocum and colleagues 47 assessed the sensitivity of healthy individuals to a single dose of rHuPH20 in a single-center, double-blind, placebo-and within-subject-controlled study. No allergic reactions (defined as occurrence of wheal with pseudopods within 5 minutes of injection that persisted for at least 20 minutes and was accompanied by localized itching) were observed among the 100 individuals who received a single intradermal injection of rHuPH20 (i.e., 0% allergic reaction rate). 47 The incidence of any symptom of discomfort was significantly higher for saline compared with rHuPH20 (28% vs 3%, respectively; P < 0.0001), primarily because of stinging after saline injection (13%) compared with rHuPH20 (1%). The authors concluded that the higher incidence of discomfort related to injection of saline vs rHuPH20 was likely related to the rapid action of rHuPH20 as a spreading agent, effectively reducing the pressure required to inject the test agent. Taken together, observations of multiple studies highlight the potential uses and benefits of hyaluronidase administration in the clinical setting.
Effect of rHuPH20 on Insulin Absorption and Action
Mechanisms Underlying Absorption Kinetics of Subcutaneously Administered Insulin
Because most commercial drug formulations of insulin are predominately hexameric, insulin absorption is driven by the processes of both dissociation and diffusion. 48 Insulin hexamers are too large to be absorbed across capillary walls and must dissociate into dimers or monomers before absorption can occur. 48, 49 Spontaneous dissociation of insulin occurs at low concentrations via equilibrium shift. In a traditional subcutaneous injection, insulin absorption is diffusion limited; insulin hexamers must first diffuse away from the site of injection to dissociate and become available for absorption. 41 Thus, the absorption of insulin is affected by both insulin concentration and dose (Figure 2) . 48 High concentrations and high doses are absorbed more slowly because of diffusion limitations.
Hyaluronidase acts as a spreading factor by rapidly digesting high-molecular weight hyaluronan, increasing bulk fluid flow away from the site of injection by about 20-fold. 17, 30 Administration of rHuPH20 promotes rapid depolymerization of hyaluronan in the extracellular space to achieve rapid dilution of insulin to low concentrations 
Clinical Pharmacology Studies
A phase 1, glucose-clamp study compared the insulin time-concentration profile (PK) and glucodynamics of insulin lispro and regular human insulin administered with or without rHuPH20 to healthy volunteers (Table 3) . 10 Coadministration of rHuPH20 substantially increased the rate and peak level (C max ) of absorption of both insulin formulations compared with either agent alone. Although requiring a comparison across cohorts, coadministration with rHuPH20 appeared to produce an acceleration of a magnitude comparable to the faster absorption of the rapid insulin analog relative to regular insulin. Similarly, rHuPH20 coadministration resulted in accelerated glucose metabolism compared with either formulation alone. The acceleration of insulin absorption and insulin action has been confirmed and extended in two subsequent healthy volunteer studies. [24] [25] [26] In the original healthy volunteer study, it also was observed that rHuPH20 greatly reduced the intersubject variability of important PK and glucodynamic parameters, which suggested the possibility that hyaluronidase coinjection may also reduce intrasubject variability. 10 To test this hypothesis, a second healthy volunteer study was conducted in 20 subjects, each receiving two doses each of three study drugs: insulin + PH20, lispro + PH20, or lispro alone. Coadministration with rHuPH20 significantly reduced the intrasubject variability of early insulin exposure and the timing of insulin absorption. 26 The dose-normalized PK responses to regular insulin and insulin lispro with and without rHuPH20 were compared in separate studies of healthy volunteers and patients with type 1 diabetes (Figure 3) . The high doses of insulin lispro (without rHuPH20) administered in the healthy volunteer study resulted in a lower dose-normalized C max than that observed with the lower doses of insulin administered in the meal study in patients with type 1 diabetes. However, when rHuPH20 was administered with insulin lispro in these studies, the dose-normalized C max values were comparable, suggesting that coadministration of rHuPH20 may attenuate this dose-dependent nonproportionality in PK responses. This effect was further studied in a third healthy volunteer study conducted over multiple dose cohorts. The first two stages were used to examine the dose-response effect of increasing rHuPH20 concentrations on the absorption of regular insulin and insulin lispro, which was found to be accelerated over a wide concentration range (0.3 to 80 µg/ml), with an optimum Figure 2 . Diffusion-limited absorption is nonlinear such that higher insulin concentrations (A) and higher insulin doses (B) are absorbed more slowly. Reprinted with permission from Søeborg and colleagues. 48 that favor hexamer dissociation, which ultimately increases the rate of insulin absorption. 10, 23 Thus, administration of rHuPH20 has the potential to reduce concentrationand dose-mediated limitations imposed on standard insulin formulations. The net effect is to accelerate the absorption of insulin with increased peak insulin exposure (C max ) without significantly affecting overall insulin exposure (total area under the curve). 10 In addition to the promotion of hexamer dissociation, rHuPH20 accelerates absorption by the general hyaluronidase mechanism of dispersing the drug over a larger capillary bed, which improves absorption flux. effect at or about 5 µg/ml. 24 The second two stages demonstrated that a fixed ratio of rHuPH20 to insulin (5 µg rHuPH20/100 units insulin) accelerated insulin absorption and action over clinically relevant doses of insulin lispro (2 to 20 units) and regular insulin (6 to 24 units). Over these ranges, greater insulin doses showed slower rates of early insulin absorption, and this effect was generally reduced (but not eliminated) with rHuPH20 coadministration. 25 To examine how the accelerated insulin absorption impacts control of postprandial glucose excursions, a phase 2, within-patient, single-blind, crossover standardized test meal study was conducted in patients with type 1 diabetes (N = 21). 27 Insulin PK and glucose response to a liquid meal was measured after injection of regular human insulin or insulin lispro with or without coadministration of rHuPH20. As observed previously in healthy volunteers, coadministration of rHuPH20 accelerated the absorption of regular insulin and insulin lispro in patients with type 1 diabetes (Figure 4) . Coadministration of rHuPH20 with insulin lispro or regular insulin also improved the achievement of glycemic targets, such that mean peak PPG levels were reduced from 190 to 166 mg/dl with regular insulin (P = 0.017) and from 174 to 148 mg/dl with insulin lispro (P = 0.002). Thus, the 24-to 26-mg/ml reduction in peak PPG levels for coadministration of either insulin with rHuPH20 was meaningful relative to the 16-mg/dl reduction in peak PPG with lispro compared with regular insulin. Postprandial hypoglycemic excursions were generally mild and overall hypoglycemic risk was comparable for insulin lispro with or without rHuPH20, and coadministration of regular insulin with rHuPH20 reduced postprandial hypoglycemia risk compared with regular insulin alone. Based on these findings, the authors concluded that a coformulation of insulin with rHuPH20 may benefit patients with diabetes by decreasing postmeal hyperglycemic excursions without increasing the risk for hypoglycemia.
The addition of rHuPH20 to insulin lispro and regular insulin has been well tolerated and no severe or serious adverse events were observed in any of these four clinical studies. Additional clinical studies also have reported the overall safety and tolerability of rHuPH20 coadministration with other agents. [40] [41] [42] It should be noted that there is no long-term, repeat dose exposure to rHuPH20 data available; an ongoing 3-month × 3-month crossover study comparing regular insulin-PH20 to insulin lispro in 48 type 1 diabetic subjects did not uncover any safety or tolerability signals at the time of an interim safety analysis among the 22 subjects receiving regular insulin-PH20 (data not shown); longer term data in larger numbers of subjects will be needed to better address this question.
Conclusions
Coadministration of rHuPH20 with insulin or an insulin analog was well tolerated and accelerated insulin absorption by a magnitude similar to the accelerated absorption of rapid analogs relative to regular insulin. Recombinant human hyaluronidase reduced the variability of intrasubject and intersubject insulin PK and reduced the delay in absorption seen for higher doses of insulin. This genetically engineered soluble hyaluronidase shows promise as a method of establishing a more rapid insulin profile to prandial insulin, which leads to more physiologically appropriate responses to prandial nutrient challenge. This more rapid insulin absorption resulted in improved control of postprandial glucose excursions in a liquid meal challenge. Control of postprandial plasma glucose levels is critical to achieving target glycemic goals and providing successful treatment outcomes for patients with diabetes. 4, 5 In this regard, coadministration of rHuPH20 has the potential to result in substantial improvements in postprandial glycemic control. 
